Skip to content

US · TLSA · BIOTECHNOLOGY

Tiziana Life Sciences Ltd (TLSA) intrinsic value and stock valuation

$0.62as of 2026-11-21 · Mkt cap 63.63M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tiziana Life Sciences Ltd DCF and intrinsic value

InvestorsCraft values TLSA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TLSA’s statements →

Tiziana Life Sciences Ltd Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology London W1K 1NA tizianalifesciences.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-18.43M
20112025
Free cash flow
-$-12.87M
20112025
Total equity
$50K-74.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-21.13M-$-15.79M-$-22.73M-$-17.93M-$-36.93M
Net income-$-18.43M-$-11.86M-$-22.36M-$-18.92M-$-31.59M
EPSd-$-311.63K-$-222.35K-$-440.5K-$-372.73K-$-645.09K
Operating cash flow-$-12.85M-$-1.22M-$-12.42M-$-15.99M-$-16.13M
Capital expenditure-$-20K-$-20K$0.00$0.00-$-20K
Free cash flow-$-12.87M-$-1.23M-$-12.42M-$-15.99M-$-16.15M
Total assets$11.5M$11.3M$12.2M$26.5M$48.8M
Total debt$460K$110K$250K$360K$1.35M
Net debt-$-3.55M-$-3.62M-$-940K-$-17.76M-$-40.83M
Total equity$50K$3.94M$5.54M$19.6M$41.3M
Cash and short-term investments$4.01M$3.72M$1.18M$18.1M$42.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$10.3M$5.23M$10.3M$15.9M$17.8M
Selling, general and administrative expenses$0.00$10.3M$8.26M$4.76M$1.15M
Other expenses$10.9M$10.6M$12.5M$2M$18M
Operating expenses$21.1M$15.8M$22.7M$17.9M$36.9M
Cost and expenses$21.1M$15.8M$22.7M$17.9M$36.9M
Interest income$20K$810K$1.46M$0.00$0.00
Interest expense$20K$10K$10K$10K$240K
Depreciation and amortization$230K$120K$120K$60K$190K
Ebitda-$-18.18M-$-16.62M-$-21.66M-$-18.85M-$-35.53M
Operating income-$-21.13M-$-15.79M-$-22.73M-$-17.93M-$-36.93M
Total other income/expenses, net$2.7M-$-950K$940K-$-1M$970K
Income before tax-$-18.43M-$-16.75M-$-21.79M-$-18.92M-$-35.96M
Income tax expense$0.00-$-4.88M$570K$0.00-$-4.37M
Net income-$-18.43M-$-11.86M-$-22.36M-$-18.92M-$-31.59M
Weighted average shares outstanding$59.1M$53.3M$50.8M$50.8M$49M
Weighted average diluted shares outstanding$59.1M$53.3M$50.8M$50.8M$49M
Balance sheet
20252024202320222021
Cash and short-term investments$4.01M$3.72M$1.18M$18.1M$42.2M
Net receivables$4.26M$3.69M$6.05M$5.86M$5.27M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.55M$7.51M$7.34M$24.3M$48.7M
Property, plant and equipment, net$500K$190K$290K$390K$20K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$130K
Long-term investments$2.44M$3.59M$4.55M$1.81M$0.00
Total non-current assets$2.94M$3.78M$4.85M$2.19M$150K
Total assets$11.5M$11.3M$12.2M$26.5M$48.8M
Accounts payable$7.17M$5.58M$4.14M$4.96M$4.41M
Short-term debt$220K$110K$140K$120K$1.35M
Deferred revenue$530K$0.00$0.00$0.00$0.00
Total current liabilities$11.2M$7.35M$6.54M$6.66M$7.55M
Long-term debt$230K$0.00$110K$240K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$230K$0.00$110K$240K$0.00
Capital lease obligations$460K$110K$250K$360K$0.00
Total liabilities$11.4M$7.35M$6.65M$6.91M$7.55M
Common stock$120K$110K$100K$100K$100K
Retained earnings-$-44.41M-$-144.83M-$-133.68M-$-116.26M-$-108.06M
Accumulated other comprehensive income (loss)$9.68M$117M$117.1M$115.6M$119.2M
Total equity$50K$3.94M$5.54M$19.6M$41.3M
Total investments$2.44M$3.59M$4.55M$1.81M$0.00
Total debt$460K$110K$250K$360K$1.35M
Net debt-$-3.55M-$-3.62M-$-940K-$-17.76M-$-40.83M
Cash flow statement
20252024202320222021
Net income-$-18.43M-$-9.48M-$-14M-$-12.55M-$-17.36M
Depreciation and amortization$230K$100K$80K$40K$100K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$3.06M-$-440K-$-1.25M-$-950K-$-570K
Accounts receivable-$-690K-$-1.11M-$-1.14M-$-130K$320K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-12.85M-$-1.22M-$-12.42M-$-15.99M-$-16.13M
Investments in property, plant and equipment-$-20K-$-20K$0.00$0.00-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$3.04M-$-60K-$-990K-$-3.26M$100K
Common stock issued$10.2M$3.71M$130K$0.00$100K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10M$3.6M$30K-$-40K-$-20K
Net change in cash$290K$2.03M-$-13.4M-$-19.62M-$-17.59M
Cash at end of period$4.01M$2.98M$940K$14.8M$31.3M
Operating cash flow-$-12.85M-$-1.22M-$-12.42M-$-15.99M-$-16.13M
Capital expenditure-$-20K-$-20K$0.00$0.00-$-20K
Free cash flow-$-12.87M-$-1.23M-$-12.42M-$-15.99M-$-16.15M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tiziana Life Sciences Ltd

        Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

        CEO
        Ivor R. Elrifi
        Employees
        10
        Beta
        0.44

        Explore

        Frequently asked questions

        What is the intrinsic value of Tiziana Life Sciences Ltd (TLSA)?

        InvestorsCraft does not currently publish an intrinsic value for TLSA. How the IC value is calculated.

        Is TLSA undervalued?

        InvestorsCraft does not publish an undervaluation signal for TLSA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.